This study examined the effect of pediatric labeling for OxyContin on dispensing of all extended-release oxycodone products, using national data on dispensed prescriptions in outpatient retail pharmacies before and after the label change.
This Viewpoint discusses the publication of the Council of Canadian Academies report “Improving Medicines for Children in Canada.”
Laughon et al quantify progress made in neonatal studies and neonatal information in product labeling as a result of recent legislation. See related editorial by Stiers and Ward.
Momper et al compared US Food and Drug Administration–approved adult and adolescent drug dosing and assessed the utility of allometric scaling for the prediction of drug clearance in the adolescent population.
This Review describes the endocrine effects of inhaled corticosteroids in children and the properties of the various formulations as they relate to these adverse outcomes.
This Viewpoint discusses how the FDA can build upon the deeming rule to further protect youth by regulating e-cigarette advertising and flavors.
This Viewpoint discusses the need for development of pediatric medical devices.
This randomized, open-label clinical trial shows that a combination of rifapentine and isoniazid was as effective as isoniazid alone in preventing tuberculosis in children aged 2 to 17 years, had a higher treatment completion rate, and was safe. See also the editorial by Marais.
This Special Communication emphasizes the need to develop practices and policies to address adverse childhood experiences from the prenatal period through the first 3 years of life to prevent and manage stress-related disorders.
This study measures and compares the quality of resuscitative care delivered to simulated pediatric patients across a spectrum of pediatric emergency departments and general emergency departments in the United States.